Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-312 AME and Absolute Bioavailability in Healthy Males
NCT02676830Phase 1Completed
- Start
- Aug 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of K-312 in dyslipidemia. Primary endpoints: Area under the plasma-concentration time curve to last measured time point at 336 hours and Oral bioavailability based on the ratio of AUC after oral dosing to the AUC after i.v. dosing at 336 hours. Started Aug 2014; status: completed.
02
Drugs
K-312
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02676830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676830.